Intas Pharma launches its first biosimilar product in European market

New Delhi, February 23, 2015: Intas Pharmaceuticals has launched its first biosimilar product, Accofil, in Europe. The product is used to treat immune system disorders. The company said in a statement that it has launched its first biosimilar, filgrastim, in Europe through its wholly owned subsidiary Accord Healthcare.

 

The product has been recently launched under the brand Accofil and has already won two tenders, in Netherlands and UK.

 

The company also said that Intas is the only company from India to have two of its products, filgrastim and peg-filgrastim, filed for registration in the US, through its collaboration partner.

 

The launch of this product in Europe is another demonstration of commitment of Indian pharmaceutical industry to provide global healthcare at affordable prices.

Comment!
 
 






* Indicates mandatory field.
Please wait while comments are being sent...